F-1/A: Psyence Biomedical Files for Resale of Common Shares and Warrants After Business Combination

Psyence Biomedical seeks to register the resale of common shares and warrants following its recent business combination, potentially impacting the market price.

Summary

• Psyence Biomedical has filed a registration statement for the resale of 22,496,000 common shares and 570,000 warrants.
• The filing also covers the issuance of up to 13,070,000 common shares upon exercise of outstanding warrants.
• The common shares being registered include those issuable upon conversion of First Tranche Notes, shares issued for fees related to the Business Combination, and founder shares.
• The company consummated its business combination on January 25, 2024, with Newcourt Acquisition Corp.
• The filing acknowledges that the potential sale of these securities could depress the market price of Psyence Biomedical's common shares.
• The company completed a convertible debt PIPE financing, raising $2.5 million in gross proceeds.
• The initial conversion price of the First Tranche Notes is $10.00, subject to adjustments that could reduce it to $0.50 or even $0.
• Certain selling securityholders may experience a positive rate of return based on the initial purchase price of the common shares.
• The company will not receive any proceeds from the sale of securities by the selling securityholders.
• Psyence Biomedical is a foreign private issuer and an emerging growth company, subject to reduced reporting requirements.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the potential of Psyence Biomedical's clinical trials and partnerships, it also acknowledges significant risks and uncertainties, including the potential for share price depression and the company's lack of revenue.

Positives

• The company has secured $2.5 million in gross proceeds through a convertible debt PIPE financing.
• The company is pursuing a Phase IIb clinical trial to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder (AjD) due to incurable cancer.
• The company has received approval from the Australian Health Research Ethics Committee (HREC) for the 84-patient Phase IIb Study.
• The company has a first-mover advantage in both the palliative care and cancer-related AjD market upon approval.

Negatives

• The potential sale of a substantial number of securities could depress the market price of the company's common shares.
• The company did not satisfy the PIPE Investment Condition in the Business Combination Agreement.
• The company is registering for resale 300% of the number of Common Shares that would be actually issued to the Investors pursuant to the conversion of the First Tranche Notes, at an assumed conversion price of $0.50.
• The company has a limited operating history and expects a number of factors to cause its operating results to fluctuate on an annual basis, which may make it difficult to predict the future performance of Psyence.
• The company has never generated revenue and may never be profitable.

Risks

• Sales of a substantial number of our securities in the public market by the Selling Securityholders and/or by our existing shareholders could cause the price of our Common Shares to fall.
• The company will require substantial additional funding to achieve its business goals, and if it is unable to obtain this funding when needed and on acceptable terms, it could be forced to delay, limit or terminate its product development efforts.
• The psychedelic therapy and biotechnology industries are undergoing rapid growth and substantial change, which has resulted in an increase in competitors, consolidation and formation of strategic relationships.
• Current and future preclinical and clinical studies will be conducted outside the United States, and the FDA may not accept data from such studies to support any NDAs submitted after completing the applicable developmental and regulatory prerequisites (absent an IND).
• There is a high rate of failure for product candidates proceeding through clinical trials.
• We are dependent on licensed intellectual property. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing our product candidates, if approved.
• The requirements of being a public company may strain the Companys resources, divert the Company managements attention and affect the Companys ability to attract and retain qualified board members.

Future Outlook

The company plans to proceed with a Phase III trial in the United States, subject to FDA review and the opening of an IND, if the outcome of the Phase IIb Study is positive.

Industry Context

The document highlights the competitive landscape of psychedelic-assisted treatments and Psyence Biomedical's potential first-mover advantage in the palliative care and cancer-related AjD market.

Comparison to Industry Standards

• The document mentions Filament Health Corp., a Canadian company that produces natural psilocybin capsules, as a key partner and supplier of PEX010.
• The document mentions iNGEN Pty Ltd, a contract research organization (CRO) in Australia that specializes in the study of psychedelics, as a key partner for conducting the Phase IIb clinical trial.
• The document mentions Compass Pathways and their recent large-scale study on the efficacy of psilocybin in a treatment-resistant depression (TRD) population.

Stakeholder Impact

• Shareholders may experience volatility in the price of the company's common shares.
• The company's employees and partners are involved in the clinical trial process.
• Patients with adjustment disorder due to incurable cancer may benefit from the development of PEX010.

Next Steps

• The company will proceed with a Phase IIb clinical trial in Australia.
• The company will seek FDA review and potentially proceed to a Phase III trial in the United States if the Phase IIb Study is positive.
• The company will monitor the evolution of Australias regulations as they pertain to psilocybin and the conduct of clinical trials in Australia.

Key Dates

Keywords

common shares, warrants, Psyence Biomedical, business combination, resale, First Tranche Notes, PIPE financing, PEX010, Adjustment Disorder, palliative care, clinical trial